Jump to content

Amfetaminil: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
Monkbot (talk | contribs)
Bots
3,695,952 edits
m →top: Task 17: replace to-be-deprecated: |name-list-format= (1× replaced; usage: 1 of 1);
Monkbot (talk | contribs)
Bots
3,695,952 edits
m Task 18 (cosmetic): eval 8 templates: del empty params (7×); cvt lang vals (3×);
Line 37: Line 37:
}}
}}


'''Amfetaminil''' (also known as '''amphetaminil''', '''''N''-cyanobenzylamphetamine''',<ref name="MortonHall2012">{{cite book| vauthors = Morton IK, Hall JM |title=Concise Dictionary of Pharmacological Agents: Properties and Synonyms|url=https://books.google.com/books?id=tsjrCAAAQBAJ&pg=PA13|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-94-011-4439-1|pages=13–}}</ref> and '''AN-1'''; brand name '''Aponeuron''') is a [[stimulant]] drug derived from [[amphetamine]], which was developed in the 1970s and used for the treatment of [[obesity]],<ref name="pmid2874966">{{cite journal | vauthors = Harris LS | title = The stimulants and hallucinogens under consideration: a brief overview of their chemistry and pharmacology | journal = Drug and Alcohol Dependence | volume = 17 | issue = 2–3 | pages = 107–18 | date = June 1986 | pmid = 2874966 | doi = 10.1016/0376-8716(86)90002-5 }}</ref> [[ADHD]],<ref name="pmid1005547">{{cite journal | vauthors = Meyer-Probst B, Vehreschild T | title = [Influencing the lack of concentration in hyperkinetic school children with Aponeuron] | language = German | journal = Psychiatrie, Neurologie, und Medizinische Psychologie | volume = 28 | issue = 8 | pages = 491–9 | date = August 1976 | pmid = 1005547 | doi = | url = }}</ref><ref name="pmid8768943">{{cite journal | vauthors = Paclt I, Florian J, Brunclíková J, Růzicková I | title = [Effect of Aponeuron in the treatment of children with hyperkinetic syndrome] | language = Czech | journal = Ceska a Slovenska Psychiatrie | volume = 92 Suppl 1 | issue = | pages = 41–57 | date = May 1996 | pmid = 8768943 | doi = | url = }}</ref> and [[narcolepsy]].<ref>{{cite book | vauthors = Schlesser JL | title = Drugs Available Abroad - A Guide to Therapeutic Drugs Approved Outside the US. | publisher = MEDEX Books | location = Detroit | date = 1991 }}</ref> It has largely been withdrawn from clinical use following problems with [[drug abuse|abuse]].<ref name="pmid1005549">{{cite journal | vauthors = Winter E | title = [Drug abuse and dependence of the amphetamine type with special regard to Amphetaminil (Aponeuron(R))] | language = German | journal = Psychiatrie, Neurologie, und Medizinische Psychologie | volume = 28 | issue = 9 | pages = 513–25 | date = September 1976 | pmid = 1005549 | doi = | url = }}</ref> The drug is a [[prodrug]] to [[amphetamine]].<ref name="Dasgupta2012">{{cite book| first = Amitava | last = Dasgupta | name-list-style = vanc |title=Resolving Erroneous Reports in Toxicology and Therapeutic Drug Monitoring: A Comprehensive Guide|url=https://books.google.com/books?id=0mD9kKcUU8UC&pg=PT96|date=2 July 2012|publisher=John Wiley & Sons|isbn=978-1-118-34785-0|pages=96–}}</ref><ref name="LLC2014">{{cite book|author=AHC Media, LLC|title=Pediatric Trauma Care II: A clinical reference for physicians and nurses caring for the acutely injured child|url=https://books.google.com/books?id=9fucAwAAQBAJ&pg=PA118|date=17 March 2014|publisher=AHC Media, LLC|isbn=978-1-934863-59-6|pages=118–}}</ref>
'''Amfetaminil''' (also known as '''amphetaminil''', '''''N''-cyanobenzylamphetamine''',<ref name="MortonHall2012">{{cite book| vauthors = Morton IK, Hall JM |title=Concise Dictionary of Pharmacological Agents: Properties and Synonyms|url=https://books.google.com/books?id=tsjrCAAAQBAJ&pg=PA13|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-94-011-4439-1|pages=13–}}</ref> and '''AN-1'''; brand name '''Aponeuron''') is a [[stimulant]] drug derived from [[amphetamine]], which was developed in the 1970s and used for the treatment of [[obesity]],<ref name="pmid2874966">{{cite journal | vauthors = Harris LS | title = The stimulants and hallucinogens under consideration: a brief overview of their chemistry and pharmacology | journal = Drug and Alcohol Dependence | volume = 17 | issue = 2–3 | pages = 107–18 | date = June 1986 | pmid = 2874966 | doi = 10.1016/0376-8716(86)90002-5 }}</ref> [[ADHD]],<ref name="pmid1005547">{{cite journal | vauthors = Meyer-Probst B, Vehreschild T | title = [Influencing the lack of concentration in hyperkinetic school children with Aponeuron] | language = de | journal = Psychiatrie, Neurologie, und Medizinische Psychologie | volume = 28 | issue = 8 | pages = 491–9 | date = August 1976 | pmid = 1005547 }}</ref><ref name="pmid8768943">{{cite journal | vauthors = Paclt I, Florian J, Brunclíková J, Růzicková I | title = [Effect of Aponeuron in the treatment of children with hyperkinetic syndrome] | language = cs | journal = Ceska a Slovenska Psychiatrie | volume = 92 Suppl 1 | pages = 41–57 | date = May 1996 | pmid = 8768943 }}</ref> and [[narcolepsy]].<ref>{{cite book | vauthors = Schlesser JL | title = Drugs Available Abroad - A Guide to Therapeutic Drugs Approved Outside the US. | publisher = MEDEX Books | location = Detroit | date = 1991 }}</ref> It has largely been withdrawn from clinical use following problems with [[drug abuse|abuse]].<ref name="pmid1005549">{{cite journal | vauthors = Winter E | title = [Drug abuse and dependence of the amphetamine type with special regard to Amphetaminil (Aponeuron(R))] | language = de | journal = Psychiatrie, Neurologie, und Medizinische Psychologie | volume = 28 | issue = 9 | pages = 513–25 | date = September 1976 | pmid = 1005549 }}</ref> The drug is a [[prodrug]] to [[amphetamine]].<ref name="Dasgupta2012">{{cite book| first = Amitava | last = Dasgupta | name-list-style = vanc |title=Resolving Erroneous Reports in Toxicology and Therapeutic Drug Monitoring: A Comprehensive Guide|url=https://books.google.com/books?id=0mD9kKcUU8UC&pg=PT96|date=2 July 2012|publisher=John Wiley & Sons|isbn=978-1-118-34785-0|pages=96–}}</ref><ref name="LLC2014">{{cite book|author=AHC Media, LLC|title=Pediatric Trauma Care II: A clinical reference for physicians and nurses caring for the acutely injured child|url=https://books.google.com/books?id=9fucAwAAQBAJ&pg=PA118|date=17 March 2014|publisher=AHC Media, LLC|isbn=978-1-934863-59-6|pages=118–}}</ref>


== Stereochemistry ==
== Stereochemistry ==

Revision as of 21:42, 1 December 2020

Amfetaminil
Clinical data
ATC code
  • none
Legal status
Legal status
  • DE: Anlage II (Authorized trade only, not prescriptible)
Identifiers
  • 2-Phenyl-2-(1-phenylpropan-2-ylamino)acetonitrile
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.037.767 Edit this at Wikidata
Chemical and physical data
FormulaC17H18N2
Molar mass250.338 g·mol−1
3D model (JSmol)
  • N#CC(NC(C)Cc1ccccc1)c2ccccc2
  • InChI=1S/C17H18N2/c1-14(12-15-8-4-2-5-9-15)19-17(13-18)16-10-6-3-7-11-16/h2-11,14,17,19H,12H2,1H3 checkY
  • Key:NFHVTCJKAHYEQN-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Amfetaminil (also known as amphetaminil, N-cyanobenzylamphetamine,[1] and AN-1; brand name Aponeuron) is a stimulant drug derived from amphetamine, which was developed in the 1970s and used for the treatment of obesity,[2] ADHD,[3][4] and narcolepsy.[5] It has largely been withdrawn from clinical use following problems with abuse.[6] The drug is a prodrug to amphetamine.[7][8]

Stereochemistry

Amfetaminil is a molecule with two stereogenic centers. Thus, four different stereoisomers exist:

  • (R)-2-[(R)-1-Phenylpropan-2-ylamino]-2-phenylacetonitrile (CAS-Nr. 478392-08-4)
  • (S)-2-[(S)-1-Phenylpropan-2-ylamino]-2-phenylacetonitrile (CAS-Nr. 478392-12-0)
  • (R)-2-[(S)-1-Phenylpropan-2-ylamino]-2-phenylacetonitrile (CAS-Nr. 478392-10-4)
  • (S)-2-[(R)-1-Phenylpropan-2-ylamino]-2-phenylacetonitrile (CAS-Nr. 478392-14-2)

References

  1. ^ Morton IK, Hall JM (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 13–. ISBN 978-94-011-4439-1.
  2. ^ Harris LS (June 1986). "The stimulants and hallucinogens under consideration: a brief overview of their chemistry and pharmacology". Drug and Alcohol Dependence. 17 (2–3): 107–18. doi:10.1016/0376-8716(86)90002-5. PMID 2874966.
  3. ^ Meyer-Probst B, Vehreschild T (August 1976). "[Influencing the lack of concentration in hyperkinetic school children with Aponeuron]". Psychiatrie, Neurologie, und Medizinische Psychologie (in German). 28 (8): 491–9. PMID 1005547.
  4. ^ Paclt I, Florian J, Brunclíková J, Růzicková I (May 1996). "[Effect of Aponeuron in the treatment of children with hyperkinetic syndrome]". Ceska a Slovenska Psychiatrie (in Czech). 92 Suppl 1: 41–57. PMID 8768943.
  5. ^ Schlesser JL (1991). Drugs Available Abroad - A Guide to Therapeutic Drugs Approved Outside the US. Detroit: MEDEX Books.
  6. ^ Winter E (September 1976). "[Drug abuse and dependence of the amphetamine type with special regard to Amphetaminil (Aponeuron(R))]". Psychiatrie, Neurologie, und Medizinische Psychologie (in German). 28 (9): 513–25. PMID 1005549.
  7. ^ Dasgupta A (2 July 2012). Resolving Erroneous Reports in Toxicology and Therapeutic Drug Monitoring: A Comprehensive Guide. John Wiley & Sons. pp. 96–. ISBN 978-1-118-34785-0.
  8. ^ AHC Media, LLC (17 March 2014). Pediatric Trauma Care II: A clinical reference for physicians and nurses caring for the acutely injured child. AHC Media, LLC. pp. 118–. ISBN 978-1-934863-59-6.
Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Amfetaminil&oldid=991797562"